Compare SANG & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANG | HUMA |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.0M | 182.6M |
| IPO Year | 2018 | N/A |
| Metric | SANG | HUMA |
|---|---|---|
| Price | $4.62 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 5.5K | ★ 5.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.07 | $731.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.08 | $0.88 |
| 52 Week High | $6.46 | $3.94 |
| Indicator | SANG | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 52.42 |
| Support Level | $4.40 | $0.92 |
| Resistance Level | $4.98 | $1.25 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 40.00 | 55.73 |
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.